Last A$0.21 AUD
Change Today +0.005 / 2.44%
Volume 203.2K
IPD On Other Exchanges
Symbol
Exchange
Berlin
OTC US
As of 1:19 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

impedimed ltd (IPD) Snapshot

Open
A$0.21
Previous Close
A$0.21
Day High
A$0.21
Day Low
A$0.21
52 Week High
11/22/13 - A$0.28
52 Week Low
04/24/13 - A$0.05
Market Cap
47.6M
Average Volume 10 Days
685.2K
EPS TTM
A$-0.04
Shares Outstanding
226.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IMPEDIMED LTD (IPD)

Related News

No related news articles were found.

impedimed ltd (IPD) Related Businessweek News

No Related Businessweek News Found

impedimed ltd (IPD) Details

ImpediMed Limited develops, manufactures, and sells bioimpedance and bioimpedance spectroscopy devices, and consumables for clinicians and allied health professionals in Australia, North America, and rest of the world. The company operates through Medical and Test and Measurement segments. The Medical segment offers non-invasive medical devices for aiding in the subclinical assessment of individuals at risk of secondary lymphoedema; and monitoring body composition and hydration. The Test and Measurement segment offers power precision testing and measuring equipment. The company offers its products through distributors. ImpediMed Limited was founded in 1999 and is based in Pinkenba, Australia.

24 Employees
Last Reported Date: 02/26/14
Founded in 1999

impedimed ltd (IPD) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: A$587.8K
Chief Financial Officer
Total Annual Compensation: A$176.7K
Vice President of Product Development, Qualit...
Total Annual Compensation: A$218.0K
Vice President of Regulatory, Clinical Affair...
Total Annual Compensation: A$177.7K
Consultant
Total Annual Compensation: A$288.1K
Compensation as of Fiscal Year 2013.

impedimed ltd (IPD) Key Developments

ImpediMed Limited, Annual General Meeting, Nov 11, 2013

ImpediMed Limited, Annual General Meeting, Nov 11, 2013.

Impedimed Limited Announces Management Changes, Effective November 11, 2013

ImpediMed Limited announced the appointment of a second US Director to the Board. David Adams will join the ImpediMed Board at the AGM on November 11, 2013 upon the retirement of founding chairman Mel Bridges. Mr. Adams held previous roles at Medtronic as Vice President, Cardiovascular Business Development; Vice President Vascular Business Development and Ventures, as well as management roles in financial planning and analysis.

ImpediMed Limited Announces Management Changes

ImpediMed Limited announced the resignation of Greg Brown from his Executive Director role on the Board as of September 30, 2013. Greg's extensive history with ImpediMed is dominated by his role as Managing Director/CEO but also includes investor and consultant roles. His outstanding knowledge of bioimpedance technology and ImpediMed's IP have laid the foundation for its successful future. There will be no change to Greg's current valuable consulting role as an executive reporting to CEO Rick Carreon. In addition to Greg's resignation from the Board, ImpediMed announced the appointment and promotion of Morten Vigeland to Chief Financial Officer. Morten has been with ImpediMed since April 2011, and previously held the position of Vice President, Global Finance. Morten has more than 15 years of experience in financial management in the medical technology industry. Previous roles include Chief Financial Officer of Access Scientific Inc., a medical device company, where he completed multiple rounds of financing and corporate deals with C.R. Bard Inc. and Teleflex Inc. He was Corporate Controller for Venetec International Inc. in its emerging growth period.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IPD:AU A$0.21 AUD +0.005

IPD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IPD.
View Industry Companies
 

Industry Analysis

IPD

Industry Average

Valuation IPD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.8x
Price/Book 5.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 14.8x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMPEDIMED LTD, please visit www.impedimed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.